T3 (triiodothyronine) and T4 (thyroxine) are the two primary thyroid hormones, with T3 being 3-4 times more potent than T4. T4 makes up 93% of thyroid hormone production, while T3 accounts for only 7%. Your thyroid gland produces mostly T4, which then converts to the more active T3 in peripheral tissues through a process called deiodination. About 80% of circulating T3 comes from T4 conversion, while only 20% is directly secreted by the thyroid. T3 has a half-life of 1-2 days compared to T4's 7-day half-life, making T3 faster-acting but shorter-lasting. This conversion process is essential because T3 binds to cellular receptors 10-15 times more readily than T4, making it the primary hormone responsible for metabolic regulation.
Key Takeaways
- T3 is 3-4 times more biologically active than T4
- 80% of T3 comes from T4 conversion in peripheral tissues
- T4 has a 7-day half-life versus T3's 1-2 day half-life
- Conversion problems can cause persistent hypothyroid symptoms
- Blood tests for both hormones provide a complete thyroid picture
How T4 Converts to T3 in Your Body
T4 conversion to T3 occurs primarily in your liver, kidneys, and other peripheral tissues through the enzyme 5'-deiodinase. This enzyme removes one iodine atom from T4's outer ring, creating the more active T3. The conversion rate depends on several factors including selenium levels, zinc status, and overall health. Chronic illness, stress, and certain medications can reduce this conversion efficiency by 20-40%. Reverse T3 (rT3) represents an alternative pathway where T4 converts to an inactive form. During times of stress or illness, your body may preferentially produce rT3 instead of active T3 as a protective mechanism to slow metabolism. This shift helps conserve energy but can leave you feeling hypothyroid even with normal T4 levels.Clinical Differences Between T3 and T4 Treatment
Standard hypothyroidism treatment uses synthetic T4 (levothyroxine) because of its stable, predictable conversion to T3. T4 medication provides steady hormone levels with once-daily dosing, making it the preferred first-line treatment for most patients. Clinical studies show that 85-90% of hypothyroid patients achieve optimal symptom relief with T4-only therapy. Some patients benefit from combination therapy including both T4 and T3, particularly those with genetic variations affecting T4 conversion. Studies indicate that 10-15% of patients report improved quality of life scores with T4/T3 combinations compared to T4 alone. However, T3's short half-life requires multiple daily doses and careful monitoring to avoid hyperthyroid symptoms. Modern peptide therapy approaches sometimes incorporate thyroid optimization alongside treatments like Sermorelin for growth hormone support, as thyroid function affects overall hormone balance.Testing and Monitoring T3 vs T4 Levels
Complete thyroid assessment requires testing TSH, free T4, and free T3 to understand your thyroid function fully. Free T4 levels typically range from 0.8-1.8 ng/dL, while free T3 ranges from 2.3-4.2 pg/mL in most laboratories. The T3/T4 ratio should generally fall between 0.25-0.35 when both are measured in similar units. Patients on T4-only therapy who continue experiencing hypothyroid symptoms despite normal TSH and T4 levels may benefit from free T3 testing. Low T3 levels with adequate T4 suggest conversion problems that might require treatment adjustments or additional T3 supplementation. As telehealth options expand in 2026, many patients can access specialized thyroid testing through online platforms that offer detailed hormone panels including reverse T3 measurements.Frequently Asked Questions
Which is better for hypothyroidism treatment: T3 or T4?
T4 (levothyroxine) remains the standard first-line treatment for hypothyroidism because it provides stable, consistent hormone levels and converts naturally to T3. T4-only therapy successfully treats 85-90% of hypothyroid patients. T3 therapy is typically reserved for patients who don't respond adequately to T4 alone or have proven conversion issues.
Personalized hormone therapy for women
Work with a licensed provider to find the right hormone optimization plan for your symptoms and goals.
Start Free Assessment →View data table
| Category | Symptom Improvement (%) | Detail |
|---|---|---|
| Week 2 | 30 | Mood stabilization begins |
| Month 1 | 50 | Hot flash reduction |
| Month 3 | 72 | Significant symptom relief |
| Month 6 | 88 | Full therapeutic benefit |
Can I take T3 and T4 together?
Yes, combination T4/T3 therapy can be prescribed for patients who don't achieve optimal results with T4 alone. Common ratios range from 4:1 to 10:1 (T4:T3), mimicking natural thyroid hormone production. This approach requires careful monitoring and dose adjustments, as T3's short half-life can cause fluctuating hormone levels.
Why might my T4 be normal but T3 low?
Low T3 with normal T4 typically indicates poor peripheral conversion, often caused by nutritional deficiencies (selenium, zinc), chronic stress, illness, or certain medications. Some genetic variants also affect T4-to-T3 conversion efficiency. This pattern may require T3 supplementation or addressing underlying conversion barriers.
How quickly do T3 levels change compared to T4?
T3 levels change much faster than T4 due to their different half-lives. T3 has a 1-2 day half-life, so levels can fluctuate within days of dose changes. T4's 7-day half-life means steady-state levels take 4-6 weeks to achieve after dose adjustments, which is why thyroid retesting typically occurs 6-8 weeks after medication changes.
Sources
- Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38-89. PMID: 11844744
- Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670-751. PMID: 25266247
- Wiersinga WM, Duntas L, Fadeyev V, et al. 2012 ETA Guidelines: The use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55-71. PMID: 24783004
- Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707-721. PMID: 29621932
- Biondi B, Wartofsky L. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab. 2012;97(7):2256-71. PMID: 22593590
- Hoermann R, Midgley JE, Larisch R, Dietrich JW. Homeostatic control of the thyroid-pituitary axis. Thyroid. 2015;25(3):271-9. PMID: 25630688
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →